1. Overview of Pancreatic Cancer Biology
2. Chemoresistance in Pancreatic Cancer: Emphasis on Age and Gender
3. EMT Contributes to Chemoresistance in Pancreatic Cancer
4. Pancreatic Cancer Resistance to Gemcitabine
5. Pancreatic Cancer and Possible Therapeutic Options
6. Curcumin and Genistein Enhances the Sensitivity of Pancreatic Cancer to Chemotherapy
7. Terpenoids as Potential Targeted Therapeutics of Pancreatic Cancer: Current Advances and Future Directions
8. Small Molecules and Pancreatic Cancer Trials and Troubles
9. Targeting the Epigenome as a Therapeutic Strategy for Pancreatic Tumors - DNA and Histone Modifying Enzymes
10. Are Nanocarriers Effective for the Diagnosis and Treatment of Pancreatic Cancer?
11. Molecular Markers for Treatment Response and Toxicity of Gemcitabine
Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy, edited by Dr. Nagaraju focuses on overriding the resistance from chemotherapeutic drugs with a broader range of treatment options. It particularly focuses on stroma, tumor microenvironment, stem cells, stellate cells, transcription factors, growth factors, and important signaling pathways. This volume discusses topics such as pancreatic cancer biology, current therapeutic options, EMT, chemotherapy resistance mechanisms, and genetic manipulations and natural products to enhance the sensitivity of pancreatic cancer to chemotherapy. Additionally, it discusses small targeted molecules and pancreatic cancer trials, and nanotechnology-based drug delivery.
Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy is a valuable source for researchers and advanced students in cancer and oncology as well as clinicians and medical students who are interested in learning more about ways to break pancreatic cancer resistance to chemotherapy.
- Modulates the biologic properties of stroma in pancreatic cancer by targeting the several chemotherapy resistance mechanisms to impede their malignant property by introducing new strategies and drugs
- Provides information about on-going research as well as clinical data on pancreatic cancer and detailed descriptions about therapeutic options for easy understanding
- Utilizes full color figures to help the understanding of the content and tables for easy comparison of information as well as quick access to it
Researchers and advanced students in cancer and oncology, clinicians and medical students
- No. of pages:
- © Academic Press 2019
- 15th March 2019
- Academic Press
- Hardcover ISBN:
Dr. Nagaraju has retained an active research laboratory pursuing his own independent interests as well as collaborative projects investigating pancreatic and colon cancers with various researchers at Emory University, Kyung Hee University (South Korea), University of North Texas Health Science Center, JNTU (India) and other leading academic institutions. He conducts bench-based research and pre-clinical trials with the goal of translating biomedical research findings to the bed-side. His research has mainly focused on three areas. The first identifies signalling pathways involved in pancreatic and colon cancer growth and metastasis; he is also studying how Hsp90 and its clients comprising of both oncogenes and tumor suppressors are deregulated in pancreatic and colon cancers. The second area of his investigation focuses on how Hsp90 functional inhibitors, either directly or via modulation of other signal molecules, are involved in the development and progression of colon and pancreatic cancers; regulation of angiogenesis by HIF-1α, a client of Hsp90 and its biological significance has been another major focus in this research. The third area of Dr. Nagaraju’s investigation examines the role of curcumin and its analogues on the inhibition pathways associated with pancreatic and colon cancer progression and metastasis. Dr. Nagaraju has mentored students and residents and published in many peer-reviewed journals in all of his research projects; therefore, he is suitable to be an Editor for this volume.
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA